Cargando…
Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, the...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820366/ https://www.ncbi.nlm.nih.gov/pubmed/36613860 http://dx.doi.org/10.3390/ijms24010416 |
_version_ | 1784865449011314688 |
---|---|
author | Komissarov, Alexey A. Kislova, Maria Molodtsov, Ivan A. Petrenko, Andrei A. Dmitrieva, Elena Okuneva, Maria Peshkova, Iuliia O. Shakirova, Naina T. Potashnikova, Daria M. Tvorogova, Anna V. Ptushkin, Vadim V. Efimov, Grigory A. Nikitin, Eugene A. Vasilieva, Elena |
author_facet | Komissarov, Alexey A. Kislova, Maria Molodtsov, Ivan A. Petrenko, Andrei A. Dmitrieva, Elena Okuneva, Maria Peshkova, Iuliia O. Shakirova, Naina T. Potashnikova, Daria M. Tvorogova, Anna V. Ptushkin, Vadim V. Efimov, Grigory A. Nikitin, Eugene A. Vasilieva, Elena |
author_sort | Komissarov, Alexey A. |
collection | PubMed |
description | The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, there are no data on the safety and efficacy of the combined vector vaccine Sputnik V in patients with CLL. Here, we analyzed and compared the magnitudes of the antibody and T cell responses after vaccination with the Sputnik V vaccine among healthy donors and individuals with CLL with different statuses of preexposure to coronavirus. We found that vaccination of the COVID-19–recovered individuals resulted in the boosting of pre-existing immune responses in both healthy donors and CLL patients. However, the COVID-19–naïve CLL patients demonstrated a considerably lower antibody response than the healthy donors, although they developed a robust T cell response. Regardless of the previous infection, the individuals over 70 years old demonstrated a decreased response to vaccination, as did those receiving anti-CD20 therapy. In summary, we showed that Sputnik V, like other vaccines, did not induce a robust antibody response in individuals with CLL; however, it provided for the development of a significant anti-COVID-19 T cell response. |
format | Online Article Text |
id | pubmed-9820366 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98203662023-01-07 Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia Komissarov, Alexey A. Kislova, Maria Molodtsov, Ivan A. Petrenko, Andrei A. Dmitrieva, Elena Okuneva, Maria Peshkova, Iuliia O. Shakirova, Naina T. Potashnikova, Daria M. Tvorogova, Anna V. Ptushkin, Vadim V. Efimov, Grigory A. Nikitin, Eugene A. Vasilieva, Elena Int J Mol Sci Article The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, there are no data on the safety and efficacy of the combined vector vaccine Sputnik V in patients with CLL. Here, we analyzed and compared the magnitudes of the antibody and T cell responses after vaccination with the Sputnik V vaccine among healthy donors and individuals with CLL with different statuses of preexposure to coronavirus. We found that vaccination of the COVID-19–recovered individuals resulted in the boosting of pre-existing immune responses in both healthy donors and CLL patients. However, the COVID-19–naïve CLL patients demonstrated a considerably lower antibody response than the healthy donors, although they developed a robust T cell response. Regardless of the previous infection, the individuals over 70 years old demonstrated a decreased response to vaccination, as did those receiving anti-CD20 therapy. In summary, we showed that Sputnik V, like other vaccines, did not induce a robust antibody response in individuals with CLL; however, it provided for the development of a significant anti-COVID-19 T cell response. MDPI 2022-12-27 /pmc/articles/PMC9820366/ /pubmed/36613860 http://dx.doi.org/10.3390/ijms24010416 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Komissarov, Alexey A. Kislova, Maria Molodtsov, Ivan A. Petrenko, Andrei A. Dmitrieva, Elena Okuneva, Maria Peshkova, Iuliia O. Shakirova, Naina T. Potashnikova, Daria M. Tvorogova, Anna V. Ptushkin, Vadim V. Efimov, Grigory A. Nikitin, Eugene A. Vasilieva, Elena Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia |
title | Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia |
title_full | Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia |
title_fullStr | Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia |
title_full_unstemmed | Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia |
title_short | Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia |
title_sort | coronavirus-specific antibody and t cell responses developed after sputnik v vaccination in patients with chronic lymphocytic leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820366/ https://www.ncbi.nlm.nih.gov/pubmed/36613860 http://dx.doi.org/10.3390/ijms24010416 |
work_keys_str_mv | AT komissarovalexeya coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT kislovamaria coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT molodtsovivana coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT petrenkoandreia coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT dmitrievaelena coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT okunevamaria coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT peshkovaiuliiao coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT shakirovanainat coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT potashnikovadariam coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT tvorogovaannav coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT ptushkinvadimv coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT efimovgrigorya coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT nikitineugenea coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia AT vasilievaelena coronavirusspecificantibodyandtcellresponsesdevelopedaftersputnikvvaccinationinpatientswithchroniclymphocyticleukemia |